Search Results - "M J Piek, Jurgen"

Patients’ and professionals’ perspectives on implementation of opportunistic salpingectomy: a mixed-method study by Gelderblom, Malou E, Van Lieshout, Laura A. M, Piek, Jurgen M. J, De Hullu, Joanne A, Hermens, Rosella P. M. G

“…Background To prevent ovarian cancer, several international societies have issued guidelines which recommend to discuss opportunistic salpingectomy with women…”
Get full text

Analysis of computer-aided diagnostics in the preoperative diagnosis of ovarian cancer: a systematic review by Koch, Anna H., Jeelof, Lara S., Muntinga, Caroline L. P., Gootzen, T. A., van de Kruis, Nienke M. A., Nederend, Joost, Boers, Tim, van der Sommen, Fons, Piek, Jurgen M. J.

“…Objectives Different noninvasive imaging methods to predict the chance of malignancy of ovarian tumors are available. However, their predictive value is…”
Get full text

Development of the Patient's Experience and Attitude Colposcopy Eindhoven Questionnaire (PEACE-q) by Pop, Victor J M, Wouters, Tirza, Bekkers, Ruud L M, Spek, Viola R M, Piek, Jurgen M J

“…No validated instruments for the evaluation of patient satisfaction in colposcopy do exist. Therefore, this study reports on the development of a Patient's…”
Get full text

Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions by Abdulrahman, Ziena, Hendriks, Natasja, J Kruse, Arnold, Somarakis, Antonios, J M van de Sande, Anna, J van Beekhuizen, Heleen, M J Piek, Jurgen, de Miranda, Noel F C C, Kooreman, Loes F S, F M Slangen, Brigitte, van der Burg, Sjoerd H, de Vos van Steenwijk, Peggy J, van Esch, Edith M G

“…BackgroundThe complete response rate of cervical high-grade squamous intraepithelial lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%…”
Get full text

Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study by Harmsen, Marline G, Arts-de Jong, Marieke, Hoogerbrugge, Nicoline, Maas, Angela H E M, Prins, Judith B, Bulten, Johan, Teerenstra, Steven, Adang, Eddy M M, Piek, Jurgen M J, van Doorn, Helena C, van Beurden, Marc, Mourits, Marian J E, Zweemer, Ronald P, Gaarenstroom, Katja N, Slangen, Brigitte F M, Vos, M Caroline, van Lonkhuijzen, Luc R C W, Massuger, Leon F A G, Hermens, Rosella P M G, de Hullu, Joanne A

“…Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to BRCA1/2 mutation carriers. This procedure decreases the elevated…”
Get full text

Peritoneal carcinomatosis after risk‐reducing surgery in BRCA1/2 mutation carriers by Harmsen, Marline G., Piek, Jurgen M. J., Bulten, Johan, Casey, Murray J., Rebbeck, Timothy R., Mourits, Marian J., Greene, Mark H., Slangen, Brigitte F. M., van Beurden, Marc, Massuger, Leon F. A. G., Hoogerbrugge, Nicoline, de Hullu, Joanne A.

“…BACKGROUND Risk‐reducing salpingo‐oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma…”
Get full text

The vulvar microbiome in lichen sclerosus and high-grade intraepithelial lesions by Pagan, Lisa, Huisman, Bertine W, van der Wurff, Michelle, Naafs, Rosanne G C, Schuren, Frank H J, Sanders, Ingrid M J G, Smits, Wiep Klaas, Zwittink, Romy D, Burggraaf, Jacobus, Rissmann, Robert, Piek, Jurgen M J, Henderickx, Jannie G E, van Poelgeest, Mariëtte I E

“…The role of the vulvar microbiome in the development of (pre)malignant vulvar disease is scarcely investigated. The aim of this exploratory study was to…”
Get full text

Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial by Steenbeek, Miranda P, Harmsen, Marline G, Hoogerbrugge, Nicoline, de Jong, Marieke Arts, Maas, Angela H E M, Prins, Judith B, Bulten, Johan, Teerenstra, Steven, van Bommel, Majke H D, van Doorn, Helena C, Mourits, Marian J E, van Beurden, Marc, Zweemer, Ronald P, Gaarenstroom, Katja N, Slangen, Brigitte F M, Brood-van Zanten, Monique M A, Vos, M Caroline, Piek, Jurgen M J, van Lonkhuijzen, Luc R C W, Apperloo, Mirjam J A, Coppus, Sjors F P J, Massuger, Leon F A G, IntHout, Joanna, Hermens, Rosella P M G, de Hullu, Joanne A

“…Most women with a BRCA1/2 pathogenic variant undergo premature menopause with potential short- and long-term morbidity due to the current method of ovarian…”
Get more information

Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients by Nieuwenhuyzen-de Boer, Gatske M, Aamran, Hanane, van den Berg, Caroline B, Willemsen, Sten, Piek, Jurgen M J, Reesink-Peters, Nathalie, Maliepaard, Marianne, van Doorn, Helena C, Polinder, Suzanne, van Beekhuizen, Heleen J

“…Knowledge of quality-of-life after cytoreductive surgery is important to counsel patients with advanced-stage epithelial ovarian cancer prior to surgery. The…”
Get full text

Cyclic activity of signal transduction pathways in fimbrial epithelium of the human fallopian tube by Ploeg, Phyllis, Uittenboogaard, Aniek, Bucks, Karlijn M. M., Lentjes‐Beer, Marjolein H. F. M., Bosch, Steven L., Rumste, Minouche M. E., Vos, M. Caroline, Diest, Paul J., Lambrechts, Sandrina, Stolpe, Anja, Bekkers, Ruud L. M., Piek, Jurgen M. J.

“…Introduction The local environment of the fallopian tube represents the optimal conditions for reproductive processes. To maintain tissue homeostasis, signal…”
Get full text

Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry by van der Ploeg, Phyllis, van Lieshout, Laura A. M., van de Stolpe, Anja, Bosch, Steven L., Lentjes-Beer, Marjolein H. F. M., Bekkers, Ruud L. M., Piek, Jurgen M. J.

“…Purpose Anti-estrogen therapy may be used as a palliative treatment option in high-grade serous ovarian carcinomas (HGSC). However, clinical implementation is…”
Get full text

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer by Piek, Jurgen M. J., van Diest, Paul J., Zweemer, Ronald P., Jansen, Jan W., Poort-Keesom, Ria J. J., Menko, Fred H., Gille, Johan J. P., Jongsma, Ans P. M., Pals, Gerard, Kenemans, Peter, Verheijen, René H. M.

“…The aim of this study was to investigate the occurrence of (pre)neoplastic lesions in overtly normal Fallopian tubes from women predisposed to developing…”
Get full text

The Human Vulvar Microbiome: A Systematic Review by Pagan, Lisa, Ederveen, Roos A M, Huisman, Bertine W, Schoones, Jan W, Zwittink, Romy D, Schuren, Frank H J, Rissmann, Robert, Piek, Jurgen M J, van Poelgeest, Mariëtte I E

“…The link between cancer and the microbiome is a fast-moving field in research. There is little knowledge on the microbiome in ((pre)malignant) conditions of…”
Get full text

Response on: reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer by Piek, Jurgen M J

Get more information

The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis by van der Ploeg, Phyllis, Uittenboogaard, Aniek, Thijs, Anna M.J., Westgeest, Hans M., Boere, Ingrid A., Lambrechts, Sandrina, van de Stolpe, Anja, Bekkers, Ruud L.M., Piek, Jurgen M.J.

“…To determine the clinical benefit of monotherapy with PI3K/AKT/mTOR inhibitors in patients diagnosed with advanced or recurrent ovarian cancer and to…”
Get full text

Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists by Gultekin, Murat, Dursun, Polat, Vranes, Boris, Laky, Rene, Bossart, Michaela, Grabowski, Jacek P, Piek, Jurgen M J, Manchanda, Ranjit, Grimm, Christoph, Dallaku, Kastriot, Babloyan, Syuzanna, Moisei, Anna, Van Gorp, Toon, Cadron, Isabelle, Markov, Peter, Micevska, Ana, Halaska, Michael, Steffensen, Karina Dahl, Gristsenko, Liidia, Nissi, Ritva, Lambaudie, Eric, Tsitsishvili, Zaza, Haidopoulos, Dimitrios, Tsolakidis, Dimitrios, Novak, Zoltan, Peiretti, Michele, Dunenova, Gauhar, Macuks, Ronalds, Hetland, Thea E, Michelsen, Trond M, Martins, Filipe C, Achimas-Cadariu, Patriciu, Ulrikh, Elena A, Uharcek, Peter, Malic, Sladjana, Ognjenovic, Dejan, Zapardiel, Ignacio, Johann, Silke, Sukhin, Vladyslav S

“…The objectives of the study were to highlight some of the differences in training systems and opportunities for training in gynecologic oncology across Europe…”
Get more information

Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective by Lof, Pien, van Soolingen, Neeltje J., Piek, Jurgen M.J., Aarts, Johanna W.M., Retèl, Valesca P., Bukman, Maarten, Smorenburg, Carolina H., van Driel, Willemien J., Amant, Frédéric, Trum, Johannes W., Lok, Christianne A.R.

“…Treatment of advanced-stage ovarian cancer contains cytoreductive surgery (CRS) and chemotherapy. Achieving successful CRS (≤ 1 cm residual disease) is…”
Get full text

Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium by van der Ploeg, Phyllis, Uittenboogaard, Aniek, Bosch, Steven L., van Diest, Paul J., Wesseling-Rozendaal, Yvonne J.W., van de Stolpe, Anja, Lambrechts, Sandrina, Bekkers, Ruud L.M., Piek, Jurgen M.J.

“…To determine the activity of key signal transduction pathways in serous tubal intraepithelial carcinoma (STIC) and concurrent high-grade serous carcinoma…”
Get full text

Re: The Association Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study by van Diest, Paul J, Zweemer, Ronald P, Piek, Jurgen M J

Get full text

Primary prevention of ovarian cancer: a patient decision aid for opportunistic salpingectomy by van Lieshout, Laura A.M., Gelderblom, Malou E., de Hullu, Joanne A., The, Regina, van Ginkel, Alexandra A., Oerlemans, Anke J.M., Smeets, Kirsten M.W.H., Schreurs, Malou P.H., Piek, Jurgen M.J., Hermens, Rosella P.M.G.

“…The discovery of the fallopian tube epithelium as the origin of high-grade serous ovarian cancer has brought a new option for ovarian cancer prevention. The…”
Get full text